Blueprint Medicines (BPMC) Tops Q4 EPS by 22c ; Offers Guidance

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.82), $0.22 better than the analyst estimate of ($2.04). Revenue for the quarter came in at $71.95 million versus the consensus estimate of $66.92 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $360-390 million, versus the consensus of $391 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus